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A cytoplasmic long noncoding RNA
LINC00470 as a new AKT activator to
mediate glioblastoma cell autophagy
Changhong Liu1,2,3,4, Yan Zhang1,2,3,4, Xiaoling She5, Li Fan6, Peiyao Li1,2,3,4, Jianbo Feng1,2,3,4, Haijuan Fu1,2,3,4,
Qing Liu7, Qiang Liu8, Chunhua Zhao1,2,3,4, Yingnan Sun1,2,3,4 and Minghua Wu2,3,4*
Abstract
Background: Despite the overwhelming number of investigations on AKT, little is known about lncRNA on AKT
regulation, especially in GBM cells.
Methods: RNA-binding protein immunoprecipitation assay (RIP) and RNA pulldown were used to confirm the
binding of LINC00470 and fused in sarcoma (FUS). Confocal imaging, co-immunoprecipitation (Co-IP) and GST
pulldown assays were used to detect the interaction between FUS and AKT. EdU assay, CCK-8 assay, and intracranial
xenograft assays were performed to demonstrate the effect of LINC00470 on the malignant phenotype of GBM
cells. RT-qPCR and Western blotting were performed to test the effect of LINC00470 on AKT and pAKT.
Results: In this study, we demonstrated that LINC00470 was a positive regulator for AKT activation in GBM.
LINC00470 bound to FUS and AKT to form a ternary complex, anchoring FUS in the cytoplasm to increase AKT
activity. Higher pAKT activated by LINC00470 inhibited ubiquitination of HK1, which affected glycolysis, and
inhibited cell autophagy. Furthermore, higher LINC00470 expression was associated with GBM tumorigenesis and
poor patient prognosis.
Conclusions: Our findings revealed a noncanonical AKT activation signaling pathway, i.e., LINC00470 directly
interacts with FUS, serving as an AKT activator to promote GBM progression. LINC00470 has an important referential
significance to evaluate the prognosis of patients.
Keywords: LncRNA, AKT activation, Oncogene, GBM
Background
AKT is a serine/threonine kinase, also known as protein
kinase B, which plays critical roles in diverse cellular
processes such as proliferation, autophagy, metabolism,
and survival [1–4]. Aberrant AKT activation causes a
wide variety of disorders including diabetes, neurodegen-
erative syndromes, and various types of cancers. AKT is
well established as the predominant PI3K effector in
many cell types [5]. Many cancer genetic alterations de-
regulate cell signaling pathways and exert their oncogenic
effects in part through the PI3K/AKT pathway [6, 7].
Hence, there is a particularly intimate relationship be-
tween the activation of the AKT signaling pathway and
tumorigenesis. Activation of PI3K results in the phosphor-
ylation of two key residues on AKT, i.e., Thr308 in the ac-
tivation motif and Ser473 in a C-terminal hydrophobic
motif [7, 8]. AKT can translocate from the plasma
membrane to intracellular compartments, including the
cytoplasm and nucleus where it phosphorylates substrates
[9, 10]. Growth factors stimulate phosphorylated AKT to
translocate from the cytoplasm to the nucleus [11] where
AKT can be phosphorylated and activated [12]. For ex-
ample, nuclear AKT phosphorylates members of the Foxo
subfamily of forkhead transcription factors, promoting
nuclear exclusion and thereby inhibiting the transcription
of death genes [13, 14]. Evidence indicates that a number
of positive regulators, including regulatory proteins (such
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as PI3K, PTEN, PDK1) [15–17], miRNAs (such as
miRNA-7, miRNA-379, and miRNA-126) [18–21], and
long noncoding RNAs (lncRNAs, such as LINK-A,
lncRNA OIP5-AS1, and MALAT1), promote the over-
activation of AKT signaling [22–24]. Until now, the
underlying mechanism of AKT in the GBM was not
fully understood despite many years of investigation.
Recent studies have revealed the regulatory potential
of many lncRNAs involved in numerous physiological
and pathological processes [25]. LncRNAs have regula-
tory roles in gene expression at both transcriptional and
post-transcriptional levels in diverse cellular contexts
and biological processes [26]. LncRNAs are responsible
for nuclear structure integrity and can regulate the
expression of either nearby genes (acting in cis in the
nucleus) or genes elsewhere in cells (acting in trans in
the nucleus or cytoplasm) by interacting with proteins,
RNA, and DNA [27–29]. LncRNAs operate through dis-
tinct modes, such as signals, scaffolds for protein-protein
interactions, molecular decoys, or guides, to target ele-
ments in the genome [30, 31]. In addition, new types of
lncRNAs are likely to be discovered through integrated
approaches. For example, sno-lncRNA can form a nu-
clear accumulation that is enriched in RNA-binding
proteins [32].
LINC00470 (also known as C18orf2) is a long
non-coding RNA located in chromosome band 18p11.32
between RP11-16P11 and RP11-732L14 [33, 34]. Its alter-
native splicing of seven exons generates four transcripts.
Our previous data demonstrated that LINC00470 expres-
sion levels in astrocytoma were significantly higher than
those in normal brain tissues [35]. However, the role of
LINC00470 remains to be elucidated; in particular, it is
not known whether lncRNAs are involved in the regula-
tion of AKT activity in GBM.
In this study, we found that (1) LINC00470 is a positive
regulator of AKT activation and it inhibited the nuclear
translocation of phosphorylated AKT; (2) LINC00470
directly bound FUS and anchored FUS in the cytoplasm,
resulting in FUS activation; (3) LINC00470 interacted
with FUS and AKT to form a stable complex; and (4)
LINC00470 decreased the ubiquitination of HK1, which
affected glycolysis by positively regulating AKT activa-
tion in GBM tumorigenesis.
Methods
Primary tumor cell culture and cell lines
A primary tumor cell culture was performed as previously
described [36]. Astrocytoma cell lines U251 and U87 were
bought from cell banks of the Chinese Academy of
Sciences (Shanghai, China). All astrocytoma cell lines were
subjected to a short tandem repeat (STR) test. U251 and
primary tumor cells were cultured in DMEM high-glucose
medium with 10% FBS and a 1% antibiotic-antimycotic
solution (Gibco, Grand Island, NY, USA), while U87 cells
were cultured in MEM medium with 10% FBS and 1%
antibiotic-antimycotic solution at 37 °C and 5% CO2.
Antibodies and reagents
The following primary antibodies were used: AKT
(rabbit, Proteintech, 10176-2-AP, WB1:1500, IP:1:250,
RIP:1:100); FUS (rabbit, Abcam, ab23439, WB1:2000,
IP1: 200, RIP1:100); phospho-Akt (Ser473) (rabbit, Cell
Signaling, #4060, WB1:1500); phospho-Akt (Thr308)
(rabbit, Cell Signaling, #13038, WB1:1500); hexokinase I
(rabbit, Cell Signaling, #2024, WB1:1000); hexokinase II
(rabbit, Cell Signaling, #2867, WB1:1000); Flag (mouse,
Sigma-Aldrich, F1804, IP 1:200); GAPDH (mouse, Sangon,
D190090, WB 1:5000); H3 (rabbit, Beyotime, AH433, WB
1:500); and p53 (mouse, Active Motif, 39739, WB 1:1000,
RIP 1:150). MK-2206 2HCl (S1078) was purchased from
Selleck.
LncRNA, siRNAs, and transfection
Cell transfection was performed using Lipofectamine
3000 (Invitrogen-Life Technologies, Carlsbad, CA, USA)
per the manufacturer’s instructions.
RNA isolation and RT-qPCR
This procedure was carried out as previously described.
The following primers were used: LINC00470: F: 5′-CGTA
AGGTGACGAGGAGCTG-3′, R: 5′-GGGGAATGGCTT
TTGGGTCA-3′; AKT: F: 5′-GAAGGACGGGAGCAGG
C-3′, R: 5′-AAGGTGCGTTCGATGACAGT-3′; and GAP
DH: F: 5′-AATGGGCAGCCGTTAGGAAA-3′, R: 5′-GC
GCCCAATACGACCAAATC-3′.
Western blotting
Details of Western blotting were previously described
[37]. Cell lysates were prepared with GLB buffer
(10 mM Tris-HCl, pH = 7.5; 10 mM NaCl; 0.5% Triton
X-100; 10 mM EDTA) supplemented with protease
inhibitor cocktail (Bimake, Houston, TX, USA, B14001)
and phosphatase inhibitor (Bimake, B15001). Cytoplas-
mic and nuclear proteins were prepared with a Nuclear
and Cytoplasmic Protein Extraction Kit (Beyotime,
p0028). Thirty-microgram proteins were subjected to
electrophoresis in different percentages of gels according
to the molecular weight of the detected proteins.
Co-immunoprecipitation assay
For the interaction of FUS and AKT, HEK293 cells were
transfected with the indicated plasmids and extracted by
the addition of lysis buffer. For the immunoprecipitation
of endogenous FUS and AKT proteins extracted by the
addition of lysis buffer, the soluble supernatants were in-
cubated with the indicated antibodies for 1 h at 4 °C. The
immunocomplexes were then precipitated with protein
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A-Sepharose CL-4B. The immunocomplexes were washed
three times with lysis buffer, eluted by boiling in sample
buffer for SDS-PAGE, and then subjected to immunoblot
analysis.
Pulldown assay
GST fusion proteins containing various deletions of FUS
cytoplasmic domain or deletions of AKT were expressed
in U251 cells with the pGEX-4T-2 vector and were puri-
fied. The lysate was incubated for 1 h with GST-tagged
proteins and glutathione-Sepharose 4B beads. The beads
were subsequently washed three times in the lysis buffer
containing 1 mM EDTA and 0.5 mM DTT. Precipitates
were separated by SDS-PAGE and detected by Western
blotting analysis.
Cell viability and EdU assays
This procedure was carried out as previously described [35].
RNA-binding protein immunoprecipitation assay
Approximately 2 μg of the cell extract was mixed with
agarose beads, which had already precipitated with the
protein antibodies. Beads were washed briefly three
times with GLB+ lysis, and the retrieved protein was
detected by Western blotting. The co-precipitated RNAs
were detected by RT-qPCR.
Intracranial implantation mouse model
All animal experiments were approved by the Animal Care
and Use Committee of Central South University. Mouse
orthotopic xenograft model was performed as previously de-
scribed [36]. Six-week SD mice were chosen. Injection of
cyclophosphamide once every 2 days. One-centimeter inci-
sion was made on the midline, and a 1-mm burr hole was
drilled at AP =+ 1 mm and MR=− 3 mm from the bregma
at the right hemisphere. Ten microliters of 107 cell was
infused into the brain at a depth of − 5 mm from the dura,
at a speed of 1 μl/min.
Statistical analysis
All experiments were analyzed with GraphPad Prism 5
(La Jolla, CA, USA). Differences between the different
groups were tested using Student’s t test or one-way
ANOVA. The relationships between the LINC00470
expression and clinic-pathological parameters were ex-
amined using the χ2 test. The expression of LINC00470
and patients’ survival time was analyzed by single factor
and multiplicity factor analysis, and OS curves were cal-
culated using the Kaplan-Meier method with the SPSS
15.0 program (SPSS Inc., Chicago, IL, USA). Data are
expressed as the mean ± S.E.M. from at least three inde-
pendent experiments. A probability value P < 0.05 was
considered statistically significant.
Results
LINC00470 was a positive regulator of AKT activities
A vector construct containing the full-length LINC00470
with EGFP tag was developed and assessed for LINC00470
expression. LINC00470 did not have any detectable
protein-coding ability (Additional file 1: Figure S1A and B).
To investigate biological processes associated with
LINC00470 expression in GBM, Pearson correlation
analysis between LINC00470 expression and whole
genome profiling were performed in GBM samples by
TCGA databases. A total of 1802 gene expressions that
correlated with LINC00470 expression are shown in
Fig. 1a. To investigate which canonical pathways were sig-
nificantly dysregulated in GBM groups with LINC00470
expression, Fisher’s exact test was used to identify 20
canonical pathways in GBM that included PI3K-AKT sig-
naling (Fig. 1a). These analyses indicated that LINC00470
may be associated with PI3K-AKT signaling. Then, we
measured the expression levels of LINC00470, AKT, and
p-AKT in GBM cell lines and primary cultured GBM cells
by RT-qPCR (Additional file 2: Figure S2A) and Western
blotting (Additional file 2: Figure S2B). We found a
positive correlation between the expression of LINC00470
and p-AKT. In GBM, LINC00470 and AKT had no
correlation (Additional file 2: Figure S2B). Overex-
pression of LINC00470 upregulated the expression of
p-AKTT308 and p-AKTS473 (Fig. 1b). We designed
three kinds of siRNA and selected the best interfering effects
for follow-up study (Additional file 3: Figure S3), while
knockdown LINC00470 reduced p-AKTT308 and
p-AKTS473 levels (Fig. 1c). We also re-expressed
LINC00470 in the LINC00470-KD cells. Expression of
LINC00470 was elevated after LINC00470 was re-expressed
in the LINC00470-KD cells (Fig. 1d upper) and enhanced
the p-AKTT308 and p-AKTS473 level (Fig. 1d lower
panel). However, neither overexpression nor knockdown
of LINC00470 affected total AKT and PI3K expression
(Fig. 1b, c and Additional file 4: Figure S4). Therefore, we
proposed that LINC00470 modulates AKT activities pos-
sibly through a previously unidentified mechanism.
FUS interacted with both LINC00470 and AKT to form a
ternary complex in the cytoplasm
Bioinformatics (http://starbase.sysu.edu.cn/browseRbpLnc
RNA.php) predicted FUS, an RNA-binding protein associ-
ated with LINC00470, may also bind to AKT. An RIP
assay verified the interaction between LINC00470 and
FUS (Fig. 2a). A biotin-RNA pulldown assay further con-
firmed the binding between LINC00470 and FUS (Fig. 2b).
Interestingly, RNA-binding protein immunoprecipitation
of FUS, but not AKT, specifically retrieved LINC00470
(Fig. 2c). We also performed RIP assay in U87 cells; the re-
sult of RIP assay was consistent with that in U251cells
(Additional file 5: Figure S5). These results indicated that
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FUS interacted with LINC00470, but there was no direct
interaction between LINC00470 and AKT.
To examine the simultaneous existence of LINC00470,
FUS, and AKT within the same complex, a two-step Co-IP
assay was performed using HEK293 cell lysate from cells in
which HA-AKT, Flag-FUS, and pcDNA3.1-LINC00470
were co-transfected. LINC00470 was found in the final
immunoprecipitation, suggesting that LINC00470, FUS,
and AKT form a ternary complex (Fig. 2d). At the same
time, we also found LINC00470, FUS, and AKT can
form a ternary complex in U251 cells (Additional file 6:
Figure S6). In the absence of LINC00470, FUS and
AKT were co-localized in the nucleus of HEK293 cells
(Additional file 7: Figure S7 and Fig. 2e). However,
overexpression of LINC00470 anchored FUS and AKT
in the cytoplasm (Fig. 2e), while with knockdown of
LINC00470 in U251 cells, FUS and AKT translocated
from the cytoplasm to the nucleus (Fig. 2f ). The inter-
actions between FUS and AKT in the cytoplasm of
U251 cells were also verified by Western blotting
analysis (Fig. 2g left). An RNA pulldown assay showed
that the interaction of LINC00470 and AKT disap-
peared after FUS knockdown in U251 cells (Fig. 2g
right). We also found LINC00470 could not affect AKT
activation after pcDNA3.1-LINC00470 was transfected
into FUS-KD cells (Fig. 2h). The phosphorylated AKT
Fig. 1 LINC00470 positively regulated the pAKT level. a Left, a heat map of LINC00470 correlated gene-expression signatures and the functional
enrichment analysis of associated genes; right, enriched canonical pathways of the differentially expressed genes using Ingenuity Pathway
Analysis (IPA). b Western blotting detected the expression levels of AKT, p-AKTT308, and p-AKTS473 in GBM cells by transfected them with
pcDNA3.1- LINC00470. c Western blotting evaluated the expression levels of AKT, p-AKTT308, and p-AKTS473 in si-LINC00470-transfected GBM cells.
d Upper, RT-qPCR measured the expression of LINC00470 in the LINC00470-KD GBM cell lines by re-expressing LINC00470; lower, Western
blotting evaluated the expression levels of p-AKTT308 and p-AKTS473 and AKT in the LINC00470-KD GBM cells by re-expressing LINC00470. Data are
presented as the mean ± S.E.M. of three independent experiments; **p < 0.01, ***p < 0.001
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was reduced in the cytoplasm in LINC00470-knockdown
GBM cells (Fig. 2i). The data indicated that LINC00470
promoted the activation of AKT in the cytoplasm by inter-
acting with FUS.
LINC00470 anchored FUS in the cytoplasm and
phosphorylated FUS
Next, a series of LINC00470 deletion mutants were
constructed to determine the nucleotides in LINC00470
Fig. 2 FUS interacted with LINC00470 and AKT to form a ternary complex in the cytoplasm. a The interaction of LINC00470 and FUS was detected
through RIP assays in U251 cells. Data are presented as the mean ± S.E.M. of three independent experiments. **p < 0.01. b RNA pulldown showed
binding between LINC00470 and FUS. c RIP assays showed that there was no interaction between LINC00470 and AKT in U251 cells. Data are
presented as the mean ± S.E.M. of three independent experiments. d HEK293 cells were transfected with HA-AKT, Flag-FUS, and pcDNA3.1-LINC00470.
Two-step co-immunoprecipitation verified their interaction. The expression levels of LINC00470, AKT, and FUS were measured with RT-qPCR and
Western blotting, respectively. e The localization of AKT and FUS was detected by immunofluorescence staining in HEK293 cells. f The co-localization
of AKT and FUS was detected by immunofluorescence staining in U251 cells. g Left, the interactions between endogenous FUS and AKT in the
cytoplasm and nucleus were measured by co-immunoprecipitation; right, an RNA pulldown assay showed binding between endogenous LINC00470
and AKT in the cytoplasm and nucleus of U251 cells transfected by si-FUS. h Western blotting detected the expression of FUS in GBM cells transfected
by si-FUS. Expression levels of AKT and p-AKTS473 were measured by Western blotting in GBM cells that re-expressed LINC00470 in FUS-KD GBM cells.
i Western blotting detected the expression levels of p-AKTS473 in the cytoplasm and nucleus of U251 cells transfected by si-LINC00470
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that bind to FUS. An RNA pulldown assay showed that
there was an interaction between FUS and LINC00470
mutants (1–300 nt, 1–710 nt, 1–1500 nt, 1–2231 nt, and
100–2231 nt), but no interaction between FUS and other
LINC00470 deletion mutants (1–100 nt, 300–2231 nt,
710–2231 nt, 1500–2231 nt, 300–710 nt, 300–1500 nt,
and 710–1500 nt) (Fig. 3a), suggesting that the 100–300 nt
region of LINC00470 was responsible for its binding to
FUS. We also found FUS bound to LINC00470 through its
RNA recognition domain (RRM) (Fig. 3b). Confocal fluor-
escence microscopy indicated that LINC00470 and FUS
were mainly co-localized in the cytoplasm in HEK 293 cells
after overexpression of LINC00470 (Fig. 3c).
FUS was reported to be continuously shuttling
between the nucleus and the cytoplasm [38]. FUS con-
tains multiple post-translational modification sites in
the RRM and GGR domain, and post-translational
modifications of FUS have profound effects on its
binding capacity of DNA, RNA and proteins, changes
in protein stability, or subcellular localization [39, 40]. We
speculated that LINC00470 may impact FUS subcellular
localization. The nuclear localization of FUS was explored
by transient expression of the GFP-FUS fusion plas-
mid in HEK293 cells (Fig. 3d). When HEK293 cells
were co-transfected by pcDNA3.1-LINC00470 and the
GFP-FUS fusion plasmid, LINC00470 led to the trans-
location of FUS from the nucleus to the cytoplasm
(Fig. 3d). In GBM cells, the expression of FUS was
increased by LINC00470 overexpression and the FUS
level was significantly increased in cytoplasm; how-
ever, its expression was decreased in the nucleus
(Fig. 3e). These data suggested that LINC00470 an-
chored FUS in the cytoplasm and promoted its ex-
pression in the cytoplasm. FUS immunoprecipitation
from U251 cells after overexpression of LINC00470
was immunoblotted with anti-phospho-T (threonine
phosphorylation) antibodies to assess the level of FUS
phosphorylation; LINC00470 promoted phosphorylation of
FUS at threonine residues (Fig. 3f). In addition, we also
found that LINC00470 was mainly located in the
cytoplasm in GBM cells by RNA fluorescence in situ
hybridization (Fig. 3g).
Fig. 3 LINC00470 anchored FUS in the cytoplasm and phosphorylated FUS. a Upper, schematic illustration of substitution mutant constructs of
LINC00470; middle and lower, an RNA pulldown assay examined the interaction between FUS and the different mutants of LINC00470. b GST
pulldown assays showed that the RRM domain of FUS pulled down LINC00470. c Representative immunofluorescence staining displayed the
co-localization of LINC00470 and FUS in the cytoplasm of HEK293 cells after LINC00470 overexpression. Scale bar, 20 μm. d Representative
imaging of LINC00470 anchoring FUS in the cytoplasm in HEK293 cells. Scale bar, 20 μm. e Western blotting measured the expression of FUS in
whole cell lysis and the cytoplasm and nucleus in U251 cells transfected by pcDNA3.1-LINC00470. f Representative immunoprecipitation analysis
detected FUS phosphorylation in U251 cells transfected by pcDNA3.1-LINC00470. FUS immunoprecipitated from U251 cells was immunoblotted
with pan-phospho-S/TQ antibodies to assess the phosphorylation level of FUS. g RNA fluorescence in situ hybridization showed the localization
of LINC00470 in GBM cells. The nucleus was counterstained with DAPI. Scale bar, 29 μm
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FUS bound to AKT and promoted AKT nuclear
translocation and activation
The “Scansite 2.0” software was utilized to identify a dock-
ing domain (GGR domain) in FUS, which is an AKT
kinase-binding site. GFP-FUS and RFP-AKT expression
plasmids were co-transfected into HEK293 cells, CO-IP
and immunofluorescence suggested there were interactions
between FUS and AKT, and both were co-localized in the
nucleus of HEK293 cells (Fig. 4a, b). In addition, we
confirmed that endogenous AKT interacted with FUS in
the cytoplasm of U251 cells (Fig. 4c, d). Next, a fusion pro-
tein of the GGR domain mutation in FUS (GST-FUS-GGR
domain) was constructed. A GST pulldown assay indicated
that AKT was precipitated with the GST-FUS-GGR
peptide (Fig. 4e left) and FUS mainly bound with the N
domain of AKT (Fig. 4e right). Then, we analyzed the
changes in AKT protein levels after silencing FUS.
Knockdown of FUS did not affect AKT expression.
Similarly, FUS expression was not affected by silen-
cing AKT (Fig. 4f ). However, we observed that FUS
influenced the subcellular localization of AKT by pro-
moting AKT nuclear translocation and increased AKT
activation in the nucleus (Fig. 4g).
LINC00470 decreased ubiquitination of HK1 to affect
glycolysis by positively regulating AKT activation
AKT, which is frequently dysregulated in cancer, is a
well-established regulator of glucose metabolism [41].
Fig. 4 FUS bound to AKT and promoted AKT activation. a Co-IP analysis measured the exogenous interaction between FUS and AKT in HEK293
cells. b Representative immunofluorescence staining displayed the co-localization of FUS and AKT in the nucleus of HEK293 cells. c Co-IP analysis
measured the endogenous interaction between FUS and AKT in U251 cells. d Representative immunofluorescence staining displayed the
endogenous co-localization of FUS and AKT in the cytoplasm of U251 cells. e Left, GST pulldown assays showed that the GGR domain of FUS
pulled down AKT; right, GST pulldown assays showed that the N-terminal region of AKT mainly pulled down FUS. f Upper, Western blotting
measured the expression levels of FUS and AKT in GBM cells transfected by si-FUS; lower, Western blotting measured the expression levels of AKT
and FUS in GBM cells transfected with si-AKT. g Western blotting measured the expression levels of AKT and pAKT in the whole lysis, cytoplasm,
and nucleus of U251 cells transfected by pcDNA3.1-FUS
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Its regulation on metabolic processes is required for
tumor proliferation, apoptosis, and autophagy [42–44].
Enforcing or silencing LINC00470 expression in GBM
cells increased or reduced glycolysis uptake and lac-
tate production, respectively (Fig. 5a, b). Hexokinases
catalyze the first and irreversible step of glucose me-
tabolism, i.e., the ATP-dependent phosphorylation of
glucose to yield glucose-6-phosphate [45]. Overex-
pression of LINC00470 increased the total hexokinase
activity in U251 cells compared to controls, and HK
activity was inhibited after knockdown of LINC00470
in U251 cells (Fig. 5c). HK1 is a major isoform of HK
and is the first key enzyme in the glycolysis pathway
[45]. Importantly, the protein expression level of HK1
was markedly increased in response to LINC00470
overexpression (Fig. 5d). In contrast, we found that
HK2, another major isoform of HK, was not changed
statistically significantly in LINC00470-overexpressed
cells (Fig. 5d).
Next, we explored the molecular mechanisms underlying
the LINC00470 that affects the activity of HK1. Inhibiting
the activity of AKT with MK-2206 resulted in downregu-
lated of HK1 (Fig. 5e). Additionally, we transfected both
pcDNA3.1 and pcDNA3.1-LINC00470 vectors into U251
Fig. 5 LINC00470 inhibited HK1 ubiquitination to affect glycolysis by positively regulating AKT activation. a RT-qPCR measured the expression of
LINC00470 in the GBM cell lines; GBM cells were transfected with si-LINC00470 or pcDNA3.1-LINC00470. Data are presented as the mean ± S.E.M.
of three independent experiments; *p < 0.05, **p < 0.01. b Relative levels of glucose uptake and lactate production were detected in GBM cells.
GBM cells were transfected with si-LINC00470 or pcDNA3.1-LINC00470. Data are presented as the mean ± S.E.M. of three independent
experiments; *p < 0.05, **p < 0.01. c HK activity was measured at different time points after GBM cells were transfected with pcDNA3.1-LINC00470
or si-LINC00470. Data are presented as the mean ± S.E.M. of three independent experiments; **p < 0.01, ***p < 0.001. d Western blotting detected
the expression levels of HK1 and HK2 in GBM cells transfected by LINC00470. e Upper, Western blotting detected the expression levels of
p-AKTS473 and HK1 in U251 cells. The cells were treated with different concentrations of AKT inhibitor (MK-2206; +, 1 μM; +++++, 5 μM); lower,
Western blotting detected the expression levels of HK1 in the cytoplasm and nucleus in U251 cells transfected by pcDNA3.1-LINC00470. f The
half-life of HK1 was assessed in U251 cells. Cells were transfected with pcDNA3.1-LINC00470. g The relative amount of ubiquitination HK1 was
determined by a ubiquitination assay in U251 cells transfected by LINC00470 or si-AKT and LINC00470
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cells, then analyzed the protein levels of HK1 in the
cytoplasm and nucleus. HK1 expression increased in the
cytoplasm under different experimental conditions;
concomitantly, HK1 expression in the nucleus did not
change significantly (Fig. 5e). To determine how HK1
protein changed, we treated U251 cells with cyclohexi-
mide (CHX) and analyzed the stability of HK1 in re-
sponse to LINC00470 overexpression. The half-life of
Fig. 6 LINC00470 promoted the tumorigenesis of GBM cells. a Expression levels of LINC00470 were measured by RT-qPCR in primary cultured GBM cells
(LINC00470 had relatively low expression in PG-1 and PG-2; LINC00470 had relatively high expression in PG-3 and PG-4). Primary cultured GBM cells were
transfected with si-LINC00470 or pcDNA3.1-LINC00470. Data are presented as the mean ± S.E.M. of three independent experiments; **p< 0.01, ***p< 0.001.
b An EDU assay was applied to assess cell proliferation of primary cultured GBM cells. Primary cultured GBM cells were transfected with pcDNA3.1-
LINC00470 or si-LINC00470. c Western blotting measured the expression levels of autophagy marker LC3, beclin-1, ATG7, and ATG5 in PG-1 and PG-3 cells.
The cells were transfected with pcDNA3.1-LINC00470 or si-LINC00470. d Electron microscopy detected the autophagy of U251 cells transfected with
pcDNA3.1-LINC00470. eWestern blotting measured the expression levels of autophagy marker LC3, beclin-1, ATG7, and ATG5 in PG-1 and PG-3 cells. The
cells were transfected with si-HK1, si-FUS or si-AKT. f Survival analysis showed that Sprague Dawley rats transplanted with U251-sh-LINC00470 cells have
longer overall survival. g Tumor growth for U251-sh-control and U251-sh-LINC00470 in Sprague Dawley rats.*p< 0.05, **p< 0.01. h H&E staining showed
the volume and morphology of tumors in mice transplanted with U251-sh-LINC00470 cells. The white circle represents the size of the tumor. i Western
blotting measured the expression levels of the autophagy marker LC3, beclin-1, ATG7, and ATG5 in intracranial transplanted tumors. j Expression of Ki-67
and LINC00470 in intracranial transplanted tumors was detected by immunohistochemical staining or in situ hybridization, respectively
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HK1 was much longer in LINC00470-overexpressed
cells than that in controls (Fig. 5f ). We further ex-
plored the mechanism of AKT-mediated HK1 regula-
tion and found lower HK1 ubiquitination levels in
LINC00470-transfected cells treated with MG132,
and a restoration experiment was performed by
knocking down AKT. We found that the ubiquitina-
tion level of HK1 was rescued (Fig. 5g). Together,
these observations suggested that LINC00470 affected
the ubiquitination and expression of HK1 through
activating AKT.
LINC00470 is an onco-RNA, and it induced the malignant
characteristics of GBM cells
The above data suggested that LINC00470 plays an
important role in GBMs. Accordingly, the primary
cultured cells were used to evaluate the functions of
LINC00470. As shown in Additional file 7: Figure
S7, there was relatively low expression of LINC00470
in PG-1 and PG-2 cells and relatively high expres-
sion of LINC00470 in PG-3 and PG-4 cells. There-
fore, we expected overexpression of LINC00470 in
PG-1 and PG-2 cells and knockdown of LINC00470
in PG-3 and PG-4 cells (Fig. 6a). We found overex-
pression of LINC00470 contributed to the prolifera-
tion of PG1 and PG2 cells by CCK-8 assay (Fig. 6b
and Additional file 8: Figure S8). Knockdown of
LINC00470 in PG-3 and PG-4 cells decreased cell
proliferation (Fig. 6b and Additional file 8: Figure S8).
Autophagy primarily promoted the progression of cancers
[46, 47]. We also found that, in PG-1 cells, overexpression
of LINC00470 inhibited the levels of autophagy (Fig. 6c,
d), and in PG-3 cells, knockdown of LINC00470 pro-
moted the levels of autophagy (Fig. 6c).
To evaluate whether glycolysis activation serves as
an upstream mechanism for LINC00470-mediated au-
tophagy, we monitored the markers of autophagy by
knockdown of HK1, FUS, and AKT, respectively. The
Fig. 7 LINC00470 was an independent prognostic factor in astrocytoma patients. a RT-qPCR detected the expression levels of LINC00470 in
normal brain tissues and astrocytoma. b RT-qPCR measured the expression levels of LINC00470 in astrocytoma with different WHO grades of
astrocytoma. c The expression levels of LINC00470 were detected in astrocytoma tissues via in situ hybridization. Black scale bars, 50 μm; red scale
bars, 10 μm. d Upper, the score of in situ hybridization in astrocytoma tissues; lower: Kaplan-Meier analysis for overall survival in 75 astrocytomas
in high- and low-risk groups based on LINC00470 expression levels
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results showed that when HK1, FUS, or LINC00470
was knocked down, the autophagy level of GBM did
not decrease. These results suggested that LINC00470
affected autophagy that was required for HK1, FUS,
and AKT (Fig. 6e). At the same time, we applied an
intracranial orthotopic transplanted model to evaluate
whether LINC00470 mediated GBM tumorigenesis.
Compared to mice transplanted with U251-sh-control
cells, mice transplanted with U251-sh-LINC00470
cells exhibited longer survival (Fig. 6f ), gained more
weight (Fig. 6g), and had smaller tumors (Fig. 6h).
Knockdown of LINC00470 significantly increased the
autophagy levels and decreased the expression of
Ki-67 and LINC00470 in an intracranial orthotopic
transplanted model (Fig. 6i, j).
LINC00470 was an independent prognostic factor in
astrocytoma patients
To further evaluate the clinical significance of LINC00470
in astrocytomas, including GBMs, we found that the levels
of LINC00470 were significantly increased in astrocy-
toma tissues (n = 60) compared with normal brain
tissues (n = 12) by RT-qPCR (Fig. 7a), especially in
high-grade astrocytomas (Fig. 7b). We next measured
LINC00470 levels in a panel of 75 astrocytoma tissues
and 15 normal brain tissues by in situ hybridization
(Fig. 7c). The results were consistent with those of
RT-qPCR (Fig. 7a).
Subsequently, we conducted a univariate cox regres-
sion analysis using clinical variables for astrocytoma
patients and found that expression of LINC00470, astro-
cytoma grade, patients’ age, and the astrocytoma loca-
tion were statistically associated with overall survival
(Table 1). The multivariate cox proportional hazards
model indicated that LINC00470 expression and astrocy-
toma grades were independently associated with overall
survival (hazard ratio [HR] = 2.876, P = 0.02; HR = 1.892,
P = 0.044; respectively) (Table 2). The results showed that
LINC00470 was an independent prognostic factor in
astrocytoma patients.
The patients were divided into high or low LINC00470
expression groups according to the ISH scores.
Kaplan-Meier analysis of the 75 patients with astro-
cytoma revealed that high LINC00470 expression
levels significantly correlated with shorter survival
times (Fig. 7d). High LINC00470 expression was signifi-
cantly associated with a poor prognosis of astrocytoma
patients.
Discussion
Previous studies have shown multiple signaling path-
ways that are misregulated in human glioblastomas,
such as RTK/PI3K/AKT/Foxos signaling pathway, p53,
and Rb1 tumor suppressor pathways [48]. Given the
complexity and redundancy of the signaling networks
associated with glioma, targeting of critical oncogenic
pathways might constitute a promising treatment ap-
proach [49]. For example, S109 treatment disturbed
three pathways in glioma including the RTK/AKT/
Foxos signaling pathway and the p53 and Rb1
tumor-suppressor pathways [48]. Although a multi-
tude of studies have demonstrated the importance of
PI3K in the activation of AKT, there have been re-
ports suggesting that AKT activation can proceed in a
manner that is independent of PI3K [2]. In the
present study, we provided the evidence that
LINC00470 was required for AKT cytoplasm activa-
tion and the interaction of LINC00470 and FUS was
Table 1 Correlation between the clinicopathological factors and
expression of LINC00470 in astrocytoma
Characteristic Total(N=75) LINC00470 high
expression
LINC00470 low
expression
Histologic grade*-no.(%)
Astrocytoma
I 9(12) 3(33) 6(67)
II 27(36) 14(52) 13(48)
III 18(24) 13(72) 15(28)
IV 21(28) 17(81) 4(19)
Sex-no.(%)
Male 39(52) 17(44) 22(56)
Female 36(48) 21(58) 15(42)
Age*-no.(%)
≤42 31(41) 10(33) 21(67)
>42 44(54) 35(80) 9(20)
Tumor location*-no./total no.(%)
Frontal lobe 23/72(32) 9/23(39) 14/23(61)
Parietal lobe 19/72(26) 6/19(32) 13/19(68)
Temporal lobe 13/72(19) 10/13(77) 3/13(23)
Brainstem 3/72(4) 2/3(66) 1/3(34)
others 14/72(19) 7/17(50) 7/17(50)
Laterality-no./total no.(%)
Left 32/72(44) 15/33(47) 17/33(53)
Right 25/72(35) 10/26(38) 16/26(62)
others 15/72(21) 7/16(43) 9/16(57)
Presenting symptom-no./total no.(%)
Seizure 38/70(54) 21/38(55) 17/38(45)
Headache 12/70(17) 6/12(50) 6/12(50)
Sensory or visual
change
9/70(13) 5/9 (56) 4/9(44)
Mental statue change 11/70(16) 6/11(55) 5/11(45)
Categorical distributions were compared with the use of Fisher’s exact test.
*P<0.01 for the difference among the molecular subtypes.
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critical for AKT activation. Our results provided a new
mechanism for AKT activity regulation, and we uncovered
noncanonical AKT activation signaling by long non-coding
RNA.
Recently, the study of lncRNAs has become import-
ant, with emerging evidence indicating that lncRNAs
function as oncogenes and tumor suppressors, thus
having an impact on one or more of the cancer
hallmarks [50, 51]. The roles of a small number of
lncRNAs such as HOTAIR, H19, and MALAT1 have
been depicted in cancers, but little is known about
LINC00470. Our study suggested an oncogenic role
for LINC00470 in GBM. This was based on the following
lines of evidence: (1) LINC00470 was upregulated in GBM
and its expression was positively correlated with p-AKT;
(2) ectopic expression of LINC00470 or knockdown of
LINC00470 increased or suppressed AKT activity and
tumor cell proliferation, respectively; and (3) re-expression
Table 2 Summary of multivariate analysis of Cox proportional
hazards model for survival of patients with astrocytoma
Variable Univarible
Regression
Multivariable
Regression
HR P HR P
Gender(Female vs. Male) 1.23 0.244 1.150 0 .593
Age 1.46 0.332 1.398 0.475
Grade
I+II vs. III + IV 1.741 0.051 1.892 0.044
Tumor location 1.021 0.871 1.566 0.111
Laterality 1.381 0.211 1.522 0.169
Presenting symptom 0.721 0.879 0.901 0.351
HighLINC00470 expression 2.113 0.030 2.876 0.021
Fig. 8 A schematic diagram of the working model for the LINC00470 targeting system in GBM cells
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of LINC00470 in LINC00470-KO cells was able to restore
AKTactivation.
FUS is a member of the Ewing’s sarcoma family of
proteins that appears to translocate from the cyto-
plasm to the nucleus [52], and it is phosphorylated
in response to radiotherapy [53]. However, to date,
there is no evidence that lncRNAs can regulate FUS
localization and activation. Our study demonstrated
that FUS was a new binding partner of LINC00470.
LINC00470 bound FUS, anchored it in the cyto-
plasm, and increased FUS expression in the cyto-
plasm to activate it. Our results not only revealed
that FUS could be used as molecular scaffolding that
bound LINC00470 and AKT but also upregulated phos-
phorylated AKT. In HEK293 cells with the absence of
LINC00470, FUS was mainly located in the nucleus, and it
transported AKT to the nucleus. However, in GBM cells,
LINC00470 prevented FUS from transporting to the nu-
cleus, so AKT was also activated and anchored in the cyto-
plasm. High levels of p-AKT decreased ubiquitination of
HK1, so that the HK1 protein degradation rate was inhib-
ited, and a higher level of HK1 affected glycolysis and
inhibited cell autophagy. Our results further suggested that
LINC00470 mediated AKT activation, at least in part,
through interaction with FUS.
Finally, we confirmed the prognostic value of LINC00470
and that the high level expression of LINC00470 was an
unfavorable prognosis marker for astrocytoma patients.
Patients with high expression of LINC00470 had
shorter survival times than those with low expression
of LINC00470.
Conclusions
To summarize, we first demonstrated the function of
LINC00470 in GBM and manifested a new regulatory
mechanism for AKT activation. These results will pro-
vide a theoretical and experimental basis for verifying
the mechanism of GBM carcinogenesis and identifying
biomarkers for the early diagnosis and prognosis in
GBM (Fig. 8).
Additional files
Additional file 1: Bioinformatics analyses of evolutional conservation
and protein-coding potential of LINC00470. A: the analysis of protein coding
potential of LINC00470 using tools provided by the Peking University Center
for Bioinformatics (cpc.cbi.pku.edu.cn/programs/run_cpc.jsp) shows
LINC00470 lack of protein-coding capability. B: plasmids as schematically
shown at left were transfected to HEK293 cells (right). Immunoblotting
using antibody specific to ERK and fluorescent imaging showed that
LINC0040-EGFP plasmid did not express GFP. (DOCX 755 kb)
Additional file 2: The relationship between LINC00470, AKT, and p-AKT.
A: RT-qPCR and Western blotting measured the expression of LINC00470
and AKT in GBM cell lines and primary GBM cells. Data presented as
mean ± S.E.M. of three independent experiments. B: Western blotting
measured the expression of AKT and p-AKT in GBM cell lines and primary
GBM cells. Data showed positive correlation between the expression of
LINC00470 and p-AKT in GBM. (DOCX 302 kb)
Additional file 3: Effect of LINC00470 knockdown in GBM cells. RT-qPCR
measured the expression of LINC00470 in GBM cell lines and primary
GBM cells. Data presented as mean ± S.E.M. of three independent
experiments. (DOCX 168 kb)
Additional file 4: The expression of PI3K in GBM cells. The expression of
PI3K was measured by Western blotting in GBM cells. (DOCX 204 kb)
Additional file 5: The associate between LINC00470, FUS, and AKT in
U87 cells. A: the interaction of LINC00470 and FUS was detected through
RIP assays in U87 cells. Data are presented as the mean ± S.E.M. of three
independent experiments. **p < 0.01. B: RNA pulldown showed binding
between LINC00470 and FUS. Data are presented as the mean ± S.E.M. of
three independent experiments. C: RIP assays showed that there was no
interaction between LINC00470 and AKT in U87 cells. Data are presented
as the mean ± S.E.M. of three independent experiments. (DOCX 264 kb)
Additional file 6: LINC00470, FUS, and AKT can form a ternary complex
in U251 cells. The expression levels of LINC00470, AKT, and FUS were
measured by RT-qPCR and Western blotting, respectively. Data presented
as mean ± S.E.M. of three independent experiments. (DOCX 1262 kb)
Additional file 7: The expression levels of LINC00470 in GBM cells.
The expression levels of LINC00470 were measured by RT-qPCR.
Data presented as mean ± S.E.M. of three independent experiments.
(DOCX 129 kb)
Additional file 8: LINC00470 promoted GBM cell proliferation. CCK8
assay was performed to determine the viability of primary GBM cells.
Primary GBM cells were transfected with si-NC and si-LINC00470,
pcDNA3.1, and pcDNA3.1-LINC00470, respectively.*p < 0.05, **p < 0.01.
(DOCX 935 kb)
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